文献速递心律失常

蛋白质组标志物提升房颤风险预测:与临床及多基因风险评分的比较

Enhanced prediction of atrial fibrillation risk using proteomic markers: a comparative analysis with clinical and polygenic risk scores.
PubMed 文献 · Heart · 2024-10-10

平均随访11.8年发生2450例房颤,蛋白评分和NT-proBNP预测性能优于HARMS2-AF和多基因风险评分。

要点

  • 47蛋白风险评分可预测新发房颤,NT-proBNP为最强预测因子。
  • 测试集中蛋白评分每SD增量HR 1.94(95%CI 1.83-2.05)。
  • 蛋白评分C统计量0.802,优于临床和多基因风险评分。

核心结论

  • 基于蛋白质的风险评分,尤其是包含NT-proBNP,对房颤风险的预测价值优于传统临床和多基因风险评分。

研究设计与样本

  • 队列按70%训练集和30%测试集划分,开发并验证房颤蛋白风险评分。

主要发现

  • 平均随访11.8年,共识别2450例新发房颤。
  • 开发了47蛋白风险评分,NT-proBNP是最显著的预测因子。
  • 测试集中,蛋白风险评分每SD增量HR 1.94(95%CI 1.83-2.05),NT-proBNP单独HR 1.80(95%CI 1.70-1.91)。
  • 蛋白风险评分和NT-proBNP的C统计量分别为0.802和0.785,优于HARMS2-AF和多基因风险评分(C统计量0.751和0.748)。

临床怎么用

  • 蛋白质组数据可用于房颤风险分层,尤其是NT-proBNP的加入可能改善预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proteomic biomarkers have shown promise in predicting various cardiovascular conditions, but their utility in assessing the risk of atrial fibrillation (AF) remains unclear. This study aimed to develop and validate a protein-based risk score for predicting incident AF and to compare its predictive performance with traditional clinical risk factors and polygenic risk scores in a large cohort from the UK Biobank. METHODS: We analysed data from 36 129 white British individuals without prior AF, assessing 2923 plasma proteins using the Olink Explore 3072 assay. The cohort was divided into a training set (70%) and a test set (30%) to develop and validate a protein risk score for AF. We compared the predictive performance of this score with the HARMS2-AF risk model and a polygenic risk score. RESULTS: Over an average follow-up of 11.8 years, 2450 incident AF cases were identified. A 47-protein risk score was developed, with N-terminal prohormone of brain natriuretic peptide (NT-proBNP) being the most significant predictor. In the test set, the protein risk score (per SD increment, HR 1.94; 95% CI 1.83 to 2.05) and NT-proBNP alone (HR 1.80; 95% CI 1.70 to 1.91) demonstrated superior predictive performance (C-statistic: 0.802 and 0.785, respectively) compared with HARMS2-AF and polygenic risk scores (C-statistic: 0.751 and 0.748, respectively). CONCLUSIONS: A protein-based risk score, particularly incorporating NT-proBNP, offers superior predictive value for AF risk over traditional clinical and polygenic risk scores, highlighting the potential for proteomic data in AF risk stratification.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Liu M, Zhang Y, Ye Z, et al. Enhanced prediction of atrial fibrillation risk using proteomic markers: a comparative analysis with clinical and polygenic risk scores. Heart. 2024. PMID: 39237126. doi:10.1136/heartjnl-2024-324274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。